Skip to main content
OpenTrials
Completed

NCT Number: NCT02221219

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

Intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) are brain lesions that commonly occur in preterm infants and are well-recognized major contributors to long-term brain injury and related disabilities later in life. Despite its prevalence, long term consequences, and enormous medical and social costs, mechanisms of IVH and optimal strategies to prevent or treat its occurrence are poorly defined, especially for extremely premature infants. Only one medical therapy, prophylactic indomethacin during the first 3 days of life, has been shown to prevent or decrease the severity of IVH in preterm infants, but its use is limited by toxic side effects and debatable effects on long-term outcomes. Several small studies and case reports suggest that delayed umbilical cord-clamping (DCC) may also decrease the incidence of IVH in premature infants, but thus far these trials have indomethacin treatment mixed within their cord clamping protocols. The investigators are conducting a randomized, blinded investigation of 4 treatment groups: 1) Control (no intervention); 2) DCC alone; 3) Prophylactic indomethacin alone; 4) Combination of DCC/indomethacin, with respect to survival, IVH or PVL incidence and severity, neurodevelopmental outcomes, and relevant mechanistic effects. With the steady rise in extreme prematurity births and clear links of IVH to long-term disabilities there is a need to improve care for these patients. This multi- disciplinary project addresses an important medical problem for an understudied patient population, where the current practice has clear limitations.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The investigators will compare efficacy and safety of prophylactic indomethacin, DCC, and their combination, in affecting the incidence and severity of IVH/PVL in infants <30wks gestational age (primary outcome measure of 'fraction of survivors with no severe IVH or PVL' among the 4 groups), and longer term neurocognitive function. Other secondary endpoints and investigations include mechanistic effects of prophylactic indomethacin, DCC, and their combination (blood volume/circulatory status, inflammatory stress, progenitor cells) as well as defining relationships between clinical outcomes and mechanistic measurements among treatment groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pregnant women admitted >24weeks and <30weeks gestational age,
  • in-hospital birth (allowing for cord clamp randomization)

Exclusion criteria

  • preterm infant <24weeks or >30weeks at birth
  • maternal risks identified by obstetrician
  • fetal risks identified by obstetrician
  • any congenital abnormality of newborn infant
  • placental abruption/placental previa
  • delivery less than 2hrs from consenting to study participation

Treatment and study plan

Indomethacin

Drug

indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants

Other names: indocin

delay in umbilical cord clamp at birth

Procedure

provision of a ~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)

placebo infusion

Drug

saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)

immediate cord clamp at birth

Procedure

no delay in umbilical cord clamp; <10sec (recorded in delivery note)

Primary outcomes

  1. Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL

    Time frame: within first 60 days of life

    determined by head ultrasound in Neonatal Intensive Care Unit (NICU) and single head MRI at 38weeks corrected gestational age

Secondary outcomes

  1. Number of Participants With Acute Kidney Injury

    Time frame: first 60 days of life

    measures of serum creatinine and urine output during Neonatal Intensive Care Unit (NICU) stay. General measures of renal injury (which is a common risk of indomethacin treatment in this patient population).

Other outcomes

  1. Hematological Status

    Time frame: first 60 days of life

    hematocrit, ferritin, hemoglobin at various times during NICU stay

  2. Inflammatory Stress

    Time frame: first 60 days of life

    measurement of inflammatory biomarkers (CRP, Interleukin-6, soluble ICAM) at various times during NICU stay

  3. Circulating Progenitor Cell Subpopulations

    Time frame: first 60 days of life

    measures of several progenitor cell subtypes in blood during the NICU stay

  4. Neurocognitive Assessments at Post-NICU Followup

    Time frame: up to 24 months of corrected gestational age

    standardized neurocognitive assessments done at NICU graduate clinic.

Sponsors and collaborators

Lead sponsor

Hong Huang

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Official study title

Indomethacin and Delayed Umbilical Cord Clamp for Preterm Infant IVH

Important dates

Study start
2014
Primary completion
2019
Study completion
2021
First posted
Aug 20, 2014
Registry last updated
Nov 23, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.